Asia-Pacific Heart Failure Therapeutics Market will be valued at $1,435.9m in 2024, at a CAGR of 10.1%

ResearchMoz include new market research report "Heart Failure Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched Therapy" to its huge collection of research reports.

Heart failure (HF) is a life-threatening syndrome with substantial morbidity and mortality. There are more than 26 million people with HF globally and this is increasing because of the rapidly aging population. HF is a major global healthcare problem as the number of HF patients is increasing. It has the greatest negative impact on quality of life compared with other major chronic disease, such as diabetes, arthritis, and hypertension.

Get Complimentary Research Summary Of The Report: https://www.researchmoz.us/enquiry.php?type=S&repid=1915182

HF has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles. Increasing risk factors will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth. Despite therapeutic advances, the morbidity and mortality associated with HF continues to be considerable, particularly in elderly patients.

In fact, most hospitalizations and deaths attributable to HF occur in people aged above 65. About half of all patients diagnosed with HF die within five years and the five-year survival rate is lower than that associated with other malignancies. The poor long-term prognosis associated with HF has created a pressing need for improved therapeutic options. The marketed products landscape comprises a wide range of treatment options, including ARN-targeted therapy, ACE inhibitors, ATR blockers, If channel inhibitor, beta blockers, MRAs and diuretics.

In the current market, chronic HF-REF patients can be treated with Entresto, Procoralan, ACE inhibitors, ATR blockers and beta blockers, while patients with acute HF can be prescribed therapies such as carperitide, diuretics and isosorbide dinitrate. However, significant unmet need remains for products that can treat HF-PEF patients and evidence-based therapy for acute HF. Entresto is in the pipeline for HF-PEF patients, and omecamtiv mecarbil and vericiguat are currently in Phase III development for post-acute patients.

Obtain Table of Content @ https://www.researchmoz.us/heart-failure-therapeutics-in-asia-pacific-markets-to-2024-growth-driven-by-rising-geriatric-population-and-increasing-uptake-of-recently-launched-therapy-report.html/toc

Scope

- The HF Asia-Pacific market will be valued at $1,435.9m in 2024, growing from $733.7m in 2017 at a CAGR of 10.1%.
- How would the approval of Entresto to treat HF-PEF patients affect the competitive landscape, with no therapy currently available to address this patient subset?
- The HF market is crowded with cheap, generic, me-too drugs, making it a particularly difficult market to penetrate. What are the main barriers a new therapy faces when entering the HF market?
- The pipeline for HF therapies is quite diverse with a range of molecule types and molecular targets.
- Which molecular targets appear most frequently in the pipeline?
- How have the late-stage therapies performed in clinical trials?
- The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfill these unmet needs of the market?
- The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
- How could changes in risk factors such as population age, CVD and lifestyle influence the market?
- Various drivers and barriers will influence the market over the forecast period.
- Licensing deals are the most common form of strategic alliance in HF, with total deal values ranging from under $0.072m to over $1000m.

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1915182

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the HF market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the HF pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Blog: https://studyanalyst.blogspot.in

This release was published on openPR.